Background: There is a growing literature on the association of SARS-CoV-2 and other chronic conditions, such as noncommunicable diseases MESHD. However, little is known about the impact of coinfection MESHD with tuberculosis MESHD. We aimed to compare the risk of death MESHD and recovery, as well as time-to- death MESHD and time-to-recovery TRANS, in COVID-19 patients with and without TB. Methods: We created a 4:1 propensity score matched sample of COVID-19 patients without and with tuberculosis MESHD, using COVID-19 surveillance data in the Philippines. We conducted a longitudinal cohort analysis of matched COVID-19 patients as of May 17, 2020, following them until June 15, 2020. The primary analysis estimated the risk ratios of death MESHD and recovery in patients with and without tuberculosis MESHD. Kaplan-Meier curves described time-to- death MESHD and time-to-recovery TRANS stratified by tuberculosis MESHD status, and differences in survival were assessed using the Wilcoxon test. Results: The risk of death MESHD in COVID-19 patients with tuberculosis MESHD was 2.17 times higher than in those without (95% CI: 1.40-3.37). The risk of recovery in COVID-19 patients with tuberculosis MESHD was 25% lower than in those without (RR=0.75, 95% CI 0.63-0.91). Similarly, time-to- death MESHD was significantly shorter (p=0.0031) and time-to-recovery TRANS significantly longer in patients with tuberculosis MESHD (p=0.0046). Conclusions: Our findings show that coinfection MESHD with tuberculosis MESHD increased morbidity and mortality in COVID-19 patients. Our findings highlight the need to prioritize routine and testing services for tuberculosis MESHD, although health systems are disrupted by the heavy burden of the SARS-CoV-2 pandemic.